Clinical Trials Sponsored by MSD Sharp & Dohme GmbH, Germany

Total 143 results

Institut für Klinische Krebsforschung IKF GmbH...
Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel; MSD Sharp...

Recruiting

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC)

Biliary Tract Cancer | HER2 Gene Mutation

Germany
German Heart Institute
Charite University, Berlin, Germany; Merck Sharp & Dohme LLC

Unknown

PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites

Hypertension

Germany
InflaRx GmbH
Merck Sharp & Dohme LLC

Active, not recruiting

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

SCC - Squamous Cell Carcinoma of Skin

United States, Spain, Germany, Belgium, France
Merck Sharp & Dohme LLC
Essex Pharma GmbH

Completed

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Breast Cancer
Merck Sharp & Dohme LLC
AESCA Pharma GmbH

Terminated

Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC
AESCA Pharma GmbH

Terminated

Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED)

Rheumatoid Arthritis
Kinderwunsch Institut GmbH
Merck Sharp & Dohme LLC

Completed

Corifollitropin Alfa and Embryo Morphokinetics

Infertility

Austria
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; Merck Serono GmbH, Germany

Recruiting

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT)

Non Small Cell Lung Cancer | Advanced Cancer

United Kingdom
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
MUC Research GmbH
Merck Sharp & Dohme LLC; Pfizer; AbbVie; German Center for Infection Research

Completed

New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients (NewEra)

HIV Infections

Germany
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Completed

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer (NEOMUN)

Non-small Cell Lung Cancer (NSCLC)

Germany
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Not yet recruiting

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome (HEAT)

Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx

Germany
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) (PRIMUS)

Metastatic Squamous Non-small Cell Lung Cancer

Germany
Profil Institut für Stoffwechselforschung GmbH
Merck Sharp & Dohme LLC

Completed

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Pharmacological Action

Germany
Merck Sharp & Dohme LLC
Centocor, Inc.; Essex Pharma GmbH

Completed

Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)

Psoriasis
Genossenschaft Gesundheitsprojekt Mannheim e.G
Merck Sharp & Dohme LLC; Heidelberg University; pfm medical Institute gGmbH,...

Unknown

Randomized Control Trial to Evaluate Effectiveness of a Case Managment Program Regarding Psychosocial Well-being and Disease Symptoms Health for Patients With Multimorbid Coronary Heart Disease (CHD) Patients (KHK ProMA) (KHK ProMA)

Coronary Heart Disease | Multimorbidity

Germany
Kelly, Maureen, M.D.
Merck Sharp & Dohme LLC

Unknown

A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

Implantation, Embryo

United States
AB-CT - Advanced Breast-CT GmbH
CRO Dr. med. Kottmann GmbH; RQM+ (Germany) GmbH

Recruiting

Comparison of Low-dose Spiral Breast CT With MRI in Major Indications of MRI for Breast Diagnostics

Breast Cancer Diagnosis

Netherlands, Germany
Burdick, Daniel, M.D.
Merck Sharp & Dohme LLC

Completed

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Insomnia

United States
Merck Sharp & Dohme LLC
MDS Pharma Services

Completed

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Breast Neoplasm
Bennett, Robert, M.D.
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Fibromyalgia

United States
Charite University, Berlin, Germany
Cassella-med GmbH & Co. KG

Completed

Efficacy of Euminz® for Tension-Type Headache (CAS/B/016611)

Episodic Tension-Type Headache

Germany
Center for Epidemiology and Health Research, Germany
Merck Sharp & Dohme LLC

Completed

Nexplanon Observational Risk Assessment Study (NORA) (NORA)

Contraception

Germany
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Brain Cancer | Glioblastoma Multiforme

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Hematologic Diseases | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Bernstein, Jonathan A., M.D.
Merck Sharp & Dohme LLC

Unknown

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Rhinitis

United States
West German Study Group
Merck Sharp & Dohme LLC; Gilead Sciences

Not yet recruiting

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (ADAPT-TN-III)

Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis

Malignant Neoplasms of Male Genital Organs

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Neuromuscular Blockade on Shoulder Pain of Elderly

Malignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Urinary Tract | Malignant Neoplasms of Digestive Organs | Malignant Neoplasms of Male Genital Organs

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Investigation of Sugammadex in Outpatient Urological Procedures

Bladder Cancer | Malignant Neoplasms of Urinary Tract

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Chemoradiation-Induced Nausea and Emesis: Quality of Life

Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Vulvar Cancer | Endometrial Cancer | Anal Cancer

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Lymphoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

Ovarian Cancer

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme | Anaplastic Glioma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Sarcoma | Chemotherapy-induced Nausea and Vomiting | Effects of Chemotherapy | Adverse Effects of Medical Drugs

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Affimed GmbH
Merck Sharp & Dohme LLC; The Leukemia and Lymphoma Society

Completed

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma

United States, Spain
Center for Epidemiology and Health Research, Germany
Merck Sharp & Dohme LLC; Theramex

Completed

Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg) (PRO-E2)

Contraception

Germany
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; AstraZeneca

Active, not recruiting

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Prostate Carcinoma | Prostate Cancer Aggressiveness

United States
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene

Active, not recruiting

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
David D'Alessio, M.D.
Merck Sharp & Dohme LLC

Completed

DPP4 Inhibition & Beta Cell Function

Healthy

United States
Institut für Klinische Krebsforschung IKF GmbH...
Merck Sharp & Dohme LLC; Organon Healthcare GmbH

Active, not recruiting

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

Germany
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; InSightec

Not yet recruiting

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
North Eastern German Society of Gynaecological...
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (PERCEPTION)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Low Grade Serous Carcinoma

Germany

Clinical Trials Sponsored by MSD Sharp & Dohme GmbH, Germany

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations